2024-05-25 08:30:00 ET
Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (NYSE: DNA) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as well.
But for now, it's still trying to find its footing, and it's a riskier bet than investors may realize. So without further ado, here are three critical things you'll need to understand if you're interested in buying its shares today.
Ginkgo's biofoundry, which it also refers to as its cellular engineering-services segment, has one very complex, high-level goal. That goal is to provide a platform that biotech and pharma companies can pay to access in order to design, bioengineer, and cultivate purpose-built microorganisms, like yeast, at scale, such that the customer's desired outputs, like biomolecules or even entire organisms, are generated in suitably large volumes.
For further details see:
3 Things You Need to Know if You Buy Ginkgo Bioworks Today